National Cancer Institute to Grant Exclusive Patent License to Iovance Biotherapeutics for Cancer Treatment

Summary

The National Cancer Institute is considering granting an exclusive patent license to Iovance Biotherapeutics, Inc. to practice inventions for treating cancer, as outlined in a recent notice.